Ontology highlight
ABSTRACT:
SUBMITTER: Chen Y
PROVIDER: S-EPMC5343435 | biostudies-literature | 2017 Mar
REPOSITORIES: biostudies-literature
Chen Yunching Y Liu Ya-Chi YC Sung Yun-Chieh YC Ramjiawan Rakesh R RR Lin Ts-Ting TT Chang Chih-Chun CC Jeng Kuo-Shyang KS Chang Chiung-Fang CF Liu Chun-Hung CH Gao Dong-Yu DY Hsu Fu-Fei FF Duyverman Annique M AM Kitahara Shuji S Huang Peigen P Dima Simona S Popescu Irinel I Flaherty Keith T KT Zhu Andrew X AX Bardeesy Nabeel N Jain Rakesh K RK Benes Cyril H CH Duda Dan G DG
Scientific reports 20170309
Sorafenib is a RAF inhibitor approved for several cancers, including hepatocellular carcinoma (HCC). Inhibition of RAF kinases can induce a dose-dependent "paradoxical" upregulation of the downstream mitogen-activated protein kinase (MAPK) pathway in cancer cells. It is unknown whether "paradoxical" ERK activation occurs after sorafenib therapy in HCC, and if so, if it impacts the therapeutic efficacy. Here, we demonstrate that RAF inhibition by sorafenib rapidly leads to RAF dimerization and ER ...[more]